ARK Investment Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

ARK Investment Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-94	Closed	-$1K	–	236
2020 Q2	$1K	Buy	94 +45	+92%	+$306	﹤0.01%	213
2020 Q1	$0	Sell	49 -41,694	-100%	-$448K	﹤0.01%	217
2019 Q4	$538K	Buy	41,743 +3,300	+9%	+$30.5K	0.01%	128
2019 Q3	$404K	Sell	38,443 -90,053	-70%	-$1.18M	0.01%	161
2019 Q2	$2.18M	Sell	128,496 -9,467	-7%	-$256K	0.06%	91
2019 Q1	$4.65M	Buy	137,963 +34,614	+33%	+$1.16M	0.13%	70
2018 Q4	$3.02M	Buy	103,349 +44,328	+75%	+$1.97M	0.12%	71
2018 Q3	$3.64M	Buy	59,021 +30,644	+108%	+$2.07M	0.11%	76
2018 Q2	$2.09M	Buy	+28,377	New	+$2.21M	0.08%	86

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ARK Investment Management's BLCM Position: Q3 2020 in Review

ARK Investment Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2020, closing a stake of 94 shares — an estimated $1K sold.

ARK Investment Management first reported a position in BLCM in Q2 2018 and held it in 9 quarters. The position peaked at $4.65M in Q1 2019. 22 funds tracked by Wall St. Rank hold BLCM as of Q3 2020.

ARK Investment Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
ARK Investment Management sold 94 Bellicum Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1K.
ARK Investment Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 9 quarters.
ARK Investment Management's Bellicum Pharmaceuticals, Inc. position peaked at $4.65M in Q1 2019.
22 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2020.

Based on ARK Investment Management's 13F filing for Q3 2020, filed 30 Oct 2020.